---
layout: default
title: Secale Cereale Pollen
parent: Model Prediction Only (L5)
nav_order: 1147
evidence_level: L5
indication_count: 1
---

# Secale Cereale Pollen
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **1** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Secale Cereale Pollen: From Allergenic Product (No Recorded Indication) to Alopecia

## One-Sentence Summary

Secale cereale (rye) pollen is marketed in the US as a pollen-derived allergenic solution (Cultivated Rye, Greer Laboratories), but no approved indication text is recorded in the source data.
The TxGNN model predicts it may be effective for **alopecia**, but there are **0 clinical trials** and **0 publications** supporting this direction, so the prediction rests on the model score alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in the source data |
| Predicted New Indication | Alopecia |
| TxGNN Prediction Score | 99.01% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 6 (all listed entries are BLA101833) |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. The drug has no recorded original indications, and no drug-interaction data were found. No mechanistic link between rye pollen and alopecia can be established from the supplied data.

The only support is the TxGNN knowledge-graph score of 0.99, which is a model output, not clinical or mechanistic evidence. A score this high for a drug with no recorded indications or MOA is unusual. It may reflect sparse graph connectivity rather than a real biological signal.

Rye pollen is an allergenic product, and no plausible pathway to hair-follicle biology is documented. Similarity to the original indication and route compatibility have not been assessed. Overall, this prediction should be treated as a hypothesis-generating signal only.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| BLA101833 | Cultivated Rye (Greer Laboratories, Inc.) | Solution | Not stated in the source data |

The Evidence Pack lists five identical entries under this authorization (six licenses in total). The product is a solution, and its route category is recorded only as "Other."

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The recommendation rests only on a model score, with no clinical trials, no literature, no MOA, and no plausible biological link to alopecia. The candidate stays at stage S0 with evidence level L5.

**To proceed, the following is needed:**
- The FDA package insert (warnings, contraindications, and approved indications), which currently blocks safety screening
- Mechanism of action data from DrugBank, and a documented link between rye pollen components and hair-follicle biology
- Any preclinical, observational, or clinical evidence for alopecia, plus a check of whether the high score comes from sparse graph connectivity
- Route compatibility assessment, since the existing product is an allergen extract solution and no route suited to alopecia has been identified

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

